3692 Stock Overview
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China.
No risks detected for 3692 from our risk checks.
Hansoh Pharmaceutical Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$15.04|
|52 Week High||HK$26.20|
|52 Week Low||HK$12.00|
|1 Month Change||-3.09%|
|3 Month Change||11.91%|
|1 Year Change||-41.93%|
|3 Year Change||-36.67%|
|5 Year Change||n/a|
|Change since IPO||-22.87%|
Recent News & Updates
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued
In this article we are going to estimate the intrinsic value of Hansoh Pharmaceutical Group Company Limited ( HKG:3692...
|3692||HK Pharmaceuticals||HK Market|
Return vs Industry: 3692 underperformed the Hong Kong Pharmaceuticals industry which returned -35.7% over the past year.
Return vs Market: 3692 underperformed the Hong Kong Market which returned -20.6% over the past year.
|3692 Average Weekly Movement||6.4%|
|Pharmaceuticals Industry Average Movement||6.0%|
|Market Average Movement||6.5%|
|10% most volatile stocks in HK Market||12.6%|
|10% least volatile stocks in HK Market||3.2%|
Stable Share Price: 3692 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 3692's weekly volatility (6%) has been stable over the past year.
About the Company
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs.
Hansoh Pharmaceutical Group Fundamentals Summary
|3692 fundamental statistics|
Is 3692 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|3692 income statement (TTM)|
|Cost of Revenue||CN¥870.39m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.46|
|Net Profit Margin||27.31%|
How did 3692 perform over the long term?See historical performance and comparison
0.6%Current Dividend Yield
Is 3692 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3692?
Other financial metrics that can be useful for relative valuation.
|What is 3692's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 3692's PE Ratio compare to its peers?
|3692 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
1177 Sino Biopharmaceutical
1093 CSPC Pharmaceutical Group
874 Guangzhou Baiyunshan Pharmaceutical Holdings
3320 China Resources Pharmaceutical Group
3692 Hansoh Pharmaceutical Group
Price-To-Earnings vs Peers: 3692 is expensive based on its Price-To-Earnings Ratio (28.4x) compared to the peer average (8.7x).
Price to Earnings Ratio vs Industry
How does 3692's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 3692 is expensive based on its Price-To-Earnings Ratio (28.4x) compared to the Hong Kong Pharmaceuticals industry average (7.8x)
Price to Earnings Ratio vs Fair Ratio
What is 3692's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||28.4x|
|Fair PE Ratio||17.3x|
Price-To-Earnings vs Fair Ratio: 3692 is expensive based on its Price-To-Earnings Ratio (28.4x) compared to the estimated Fair Price-To-Earnings Ratio (17.2x).
Share Price vs Fair Value
What is the Fair Price of 3692 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 3692 (HK$15.04) is trading below our estimate of fair value (HK$28.63)
Significantly Below Fair Value: 3692 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Hansoh Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3692's forecast earnings growth (15.1% per year) is above the savings rate (1.6%).
Earnings vs Market: 3692's earnings (15.1% per year) are forecast to grow slower than the Hong Kong market (16.7% per year).
High Growth Earnings: 3692's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3692's revenue (11.7% per year) is forecast to grow faster than the Hong Kong market (9.9% per year).
High Growth Revenue: 3692's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3692's Return on Equity is forecast to be low in 3 years time (15.1%).
Discover growth companies
How has Hansoh Pharmaceutical Group performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3692 has high quality earnings.
Growing Profit Margin: 3692's current net profit margins (27.3%) are lower than last year (29.6%).
Past Earnings Growth Analysis
Earnings Trend: 3692's earnings have grown by 11.7% per year over the past 5 years.
Accelerating Growth: 3692's earnings growth over the past year (5.6%) is below its 5-year average (11.7% per year).
Earnings vs Industry: 3692 earnings growth over the past year (5.6%) underperformed the Pharmaceuticals industry 15.2%.
Return on Equity
High ROE: 3692's Return on Equity (13.5%) is considered low.
Discover strong past performing companies
How is Hansoh Pharmaceutical Group's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 3692's short term assets (CN¥23.2B) exceed its short term liabilities (CN¥3.0B).
Long Term Liabilities: 3692's short term assets (CN¥23.2B) exceed its long term liabilities (CN¥4.1B).
Debt to Equity History and Analysis
Debt Level: 3692 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 3692's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 3692's debt is well covered by operating cash flow (68.9%).
Interest Coverage: 3692 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Hansoh Pharmaceutical Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 3692's dividend (0.58%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.84%).
High Dividend: 3692's dividend (0.58%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.33%).
Stability and Growth of Payments
Stable Dividend: 3692 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Growing Dividend: 3692 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: 3692 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: 3692 is not paying a notable dividend for the Hong Kong market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Huijuan Zhong (61 yo)
Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...
Experienced Management: 3692's management team is seasoned and experienced (6.7 years average tenure).
Experienced Board: 3692's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hansoh Pharmaceutical Group Company Limited's employee growth, exchange listings and data sources
- Name: Hansoh Pharmaceutical Group Company Limited
- Ticker: 3692
- Exchange: SEHK
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$90.494b
- Shares outstanding: 5.92b
- Website: https://www.hspharm.com
Number of Employees
- Hansoh Pharmaceutical Group Company Limited
- No.45 Huanghe Road
- Economic & Technical Development Zone
- Jiangsu Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/17 00:00|
|End of Day Share Price||2022/08/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.